Streetbeat News

CYBN

Cybin Inc.

https://www.cybin.com

Industry

Biotechnology

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Open

11.82

Mkt cap

232M

Volume

2.1M

High

12.95

P/E Ratio

-2.14

52-wk high

21.66

Low

11.30

Div yield

N/A

52-wk low

6.50

Cybin Inc. has announced an offering of units up to $64 million. Each unit is comprised of one common share and one warrant.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:04 pm

California Senator Scott Wiener plans to introduce a revised bill next year to provide regulated therapeutic access to psychedelics, following Governor Gavin Newsom's veto of a broader legalization measure. The new bill, co-sponsored with Assemblymember Marie Waldron, will be crafted in response to Newsom's veto message, which called for regulated treatment guidelines before decriminalization. The bill will focus on providing access to regulated psychedelic therapies administered by licensed and vetted facilitators.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:22 pm

The U.S. Court of Appeals overruled the DEA's denial of a psilocybin rescheduling lawsuit. Psychedelics company Cybin Inc. shared positive Phase 2 study results for its psilocybin analog CYB003 on Major Depressive Disorder. Several states are discussing psychedelics reform. The AdvisorShares Psychedelics ETF (PSIL) showed a recovery in its weekly performance. Psychedelics stocks GH Research, COMPASS Pathways, Mind Medicine, Enveric Biosciences, Silo Pharma, Bright Minds Biosciences, Atai Life Sciences, Incannex Healthcare, FSD Pharma, and Cybin Inc. all closed at varying prices.

Portfolio Pulse from Lara Goldstein

November 07, 2023 | 12:02 am

A California campaign has withdrawn its proposed ballot initiative to create a $5 billion state agency for funding and promoting psychedelics research. The decision was influenced by recent polling showing 60% of likely California voters oppose state funding for psychedelic therapies. The campaign has announced the launch of a new TREAT Humanity campaign to explore mental health solutions more broadly. The proposed psychedelics institute would have identified opportunities for advancing scientific research into the therapeutic potential of psychedelics and facilitated the creation of 'care programs' for psilocybin and MDMA once approved for therapeutic use by the FDA.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 3:29 pm

Cybin Inc. (NYSE:CYBN) has shared interim results from its Phase 2 study of psilocybin analog CYB003 on Major Depressive Disorder (MDD). The results showed a significant reduction in depression symptoms three weeks after a single 12mg dose. The company also plans to share topline Phase 1 data for its proprietary deuterated DMT compounds, CYB004 and SPL028, before the end of the year. The stock price rose following the announcement of the interim results.

Portfolio Pulse from Lara Goldstein

November 01, 2023 | 8:51 pm

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Cybin (AMEX:CYBN) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:22 pm

Cybin has announced that its Phase 2 interim data for CYB003 in Major Depressive Disorder has met its primary efficacy endpoint. The data shows improvements in depression symptoms after a single dose.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:48 am

Psychedelics companies Cybin Inc. and Small Pharma Inc. have completed their acquisition agreement, making Small Pharma a wholly-owned subsidiary of Cybin. The combined company has received two patent grants from the USPTO and one from the European Patent Office. The AdvisorShares Psychedelics ETF has been showing a descending trend in its opening and closing prices. Other psychedelics stocks such as GH Research, COMPASS Pathways, Mind Medicine, Enveric Biosciences, Bright Minds Biosciences, Silo Pharma, Atai Life Sciences, Incannex Healthcare, FSD Pharma, and Cybin Inc. have also seen changes in their closing prices.

Portfolio Pulse from Lara Goldstein

October 30, 2023 | 2:48 am

Cybin (NYSE:CYBN) has received three new international patents for its deuterated psychedelics programs, two from the United States Patent and Trademark Office and one from the European Patent Office. The patents protect the composition of matter for certain deuterated DMT analogs and their medical use. The company's development programs are now protected by 33 granted patents and over 170 pending applications. Cybin is currently conducting Phase 1 clinical trials for its deuterated DMT compounds CYB004 and SPL028, and a Phase 2 clinical trial for its deuterated psilocybin analog CYB003.

Portfolio Pulse from Lara Goldstein

October 26, 2023 | 9:21 pm

Activists in California are planning to submit a proposed ballot measure this week that would legalize the use, production, and sales of most psychedelics. The proposal, called the Psychedelic Wellness and Healing Initiative of 2024, would allow people to grow psychedelic plants and fungi at home for personal use. The initiative aims to provide a path for safe, legal access to psychedelics for medical treatment, therapy, or spiritual use. The proposal would also allow businesses to cultivate, manufacture, and distribute psychedelics as a wholesaler as of January 1, 2025, and sell psychedelics from April 19, 2025.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 1:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.